Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 11/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100564 | 0.95 | FYN (0.42) | FYNLRRK2METKITALK | |
| SCHEMBL10100748 | 0.88 | ALK (0.39) | LRRK2METKITP2RX7ALK | |
| SCHEMBL10100778 | 0.88 | LRRK2 (0.42) | FYNLRRK2METKITP2RX7 | |
| SCHEMBL10100751 | 0.88 | POLB (0.40) | LRRK2METKITP2RX7ALK | |
| SCHEMBL10100777 | 0.87 | SMN1; SMN2 (0.42) | LRRK2METKITP2RX7ALK | |
| SCHEMBL10100776 | 0.87 | NTRK1 (0.40) | LRRK2METKITP2RX7ALK | |
| SCHEMBL10100706 | 0.86 | MET (0.40) | LRRK2METKITP2RX7ALK | |
| SCHEMBL10100747 | 0.86 | ALK (0.45) | FYNLRRK2METKITP2RX7 | |
| SCHEMBL10100779 | 0.85 | MET (0.43) | FYNLRRK2METKITALK | |
| SCHEMBL10100765 | 0.85 | FYN (0.45) | FYNKITP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | FYN 532/4885LRRK2 856/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.